Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Bre...(65 years) and 52% ofolder (greater than ...)

Date:12/13/2007

65 years) and 52% of older (greater than or equal to 65 years) women in the TC group, and in 54% and 59% of younger and older women, respectively, in the AC group. Among younger patients, the frequencies of Grade 3-4 febrile neutropenia were 4.4% with TC and 2.3% with AC, while in older patients the frequencies were 7.7% and 3.7% for TC and AC, respectively. Grade 3-4 nausea was less common among women in both age groups treated with TC (<65: 2%, greater than or equal to 65: 3%) than those given AC (<65: 7%, greater than or equal to 65: 5%). In the TC group, additional Grade 3-4 adverse events reported among women <65 and greater than or equal to 65 were fever in 4% and 6% and infection in 7% and 6%, respectively, while in the AC arm the rates of Grade 3-4 fever were 3% and 4% and Grade 3-4 infections were 10% and 2% for younger and older women, respectively.

Breast Cancer, the Most Common Cancer in Women

Breast cancer is the most frequently diagnosed cancer in women throughout the world. The American Cancer Society estimates that one in eight women will develop breast cancer within their lifetime. By the end of 2007, more than 178,000 American women will have learned they have invasive breast cancer. In the European Union, more than 429,900 new cases were diagnosed in 2006. Age is the biggest risk factor, and one in 26 women over 70 will have breast cancer in her lifetime.

In the U.S., breast cancer is the third-leading cause of cancer death in women. More than 40,000 women in the U.S. will die of breast cancer this year; more than half are 65 or older. In the EU, breast cancer is the leading cause of cancer death among women; an estimated 132,000 died from breast cancer in 2006.

About US Oncology, Inc.

US Oncology, headquartered in Houston, Texas, supports one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help t
'/>"/>

SOURCE sanofi-aventis Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
2. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
3. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
4. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
5. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
6. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
9. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
10. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
11. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments